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Should Language Matter Less 
to Journals?
Erik von Elm
PLoS Medicine now encourages translations in languages other 
than English; this decision can only be welcomed.
German-speaking readers are pleased by the novelty of a 
PLoS title written in their language. The Editorial starts with 
the ﬁ  rst line of the well-known German poem “Lorelei” by 
Heinrich Heine (1797–1856) [1]. This year commemorates 
the 150th anniversary of his death. Originating from 
Germany, Heine was an early European citizen and a 
mediator between cultures. After traveling through Europe 
for years, he settled down in Paris. There he wrote the 
“Lorelei” and other poems in German while his essays in 
French made German literature known to the francophone 
public.
In Heine’s time, the question which language would 
prevail in science was yet undecided. In the 19th and the 
early 20th centuries pivotal works in different disciplines 
were published in languages other than English, as 
evidenced in the biographies of the Nobel Prize laureates 
(http:⁄⁄nobelprize.org). It seems that insufﬁ  cient 
knowledge of the one foreign language did not impede an 
academic career at that time. 
Today, proﬁ  ciency in English is a luxury for many users 
of scientiﬁ  c information, as pointed out in the Editorial. 
The same is true for the non-anglophone researchers, who 
invest time and money in English courses only to try to 
communicate with their anglophone peers on equal linguistic 
terms. 
Can scientiﬁ  c journals do more to overcome the existing 
language barriers in the meantime? Sure, they can allow the 
translation of their papers in other languages. But would they 
also trouble to employ smart machines or humans in order 
to translate a manuscript written in one of Heine’s languages 
into English before sending it out for peer review? 
By the way, an English translation of the “Lorelei” is 
available at http:⁄⁄www.usd.edu/eric/deutsch/literatur/
projekt/works/heine-lorelei.html.  
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Fetal Alcohol Syndrome and Essential 
Fatty Acids
Undurti N. Das
Essential fatty acids (EFAs) are structural components of the 
brain and inﬂ  uence nerve conduction and transmitter release 
and action [1]. Prostaglandins (PGs) derived from EFAs and 
polyunsaturated fatty acids (PUFAs) modify nerve conduction 
and transmitter function. Ethanol (1) reduces blood linoleic 
acid (LA) levels; (2) blocks conversion of LA and gamma-
linolenic acid (GLA) to arachidonic acid (AA), as well as alpha-
linolenic acid (ALA) to eicosapentaenoic and docosahexaenoic 
acids (EPA and DHA, respectively), by inhibiting delta-6 
and delta-5 desaturases; and (3) enhances the conversion of 
dihomo-gamma-linolenic acid (DGLA) to PGE1 [1]. 
Ethanol-enhanced interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-alpha) production suggest that 
immunological mechanisms play a role in ethanol-induced 
diseases. Cerebral cortex from chronic ethanol-fed rats 
showed up-regulation of inducible nitric oxide (iNOS), 
cyclo-oxygenase-2 (COX-2), IL-1-beta, and activation of 
transcription factors nuclear factor-kappa B (NF-kappa B) and 
AP-1—effects that increased both caspase-3 and apoptosis [2]. 
Brains of ethanol-treated mice show raised phospholipase-
A2 and phospholipase-C activity [3] that can cause the release 
of AA, EPA, and DHA from membrane phospholipids. AA, 
EPA, and DHA form precursors to eicosanoids—lipoxins 
(LXs), resolvins, and neuroprotectin D1 (NPD1) [4]. LXs, 
resolvins, and NPD1 suppress IL-6 and TNF-alpha production. 
PGs, LXs, resolvins, and NPD1 precursor supplies are limited; 
therefore, when ethanol consumption is substantial, tissue 
concentrations of PUFAs decline, leading to a fall in the 
synthesis of various PGs, LXs, resolvins, and NPD1. 
DHA and other PUFAs released from the membrane 
in response to neurotransmitters [5] activate retinoid X 
receptor (RXR) as PUFAs form ligands for the RXR [6]. 
DHA deﬁ  ciency results in impaired spatial learning and 
other abnormalities [7]. RXR heterodimerization partners 
peroxisome proliferator-activated receptors (PPARs), liver 
X receptors, and farnesoid X receptors that are essential 
for regulating energy and nutritional homeostasis. PUFAs, 
being ligands for RXR and PPARs, modulate these and 
other regulatory events by binding to these nuclear receptor 
heterodimers.
AA, DHA, EPA, LXs, resolvins, and NPD1 have 
neuroprotective actions [4]; inhibit IL-6 and TNF-alpha 
production that is neurotoxic; and increase synthesis of 
endothelial nitric oxide (eNO), a neurotransmitter. When 
neurons are depleted of their PUFA content, as happens 
after high alcohol intake, formation of LXs, resolvins, and 
NPD1 will be suboptimal and, hence, neuronal death induced 
by TNF-alpha cannot be antagonized. This results in fetal 
alcohol syndrome (FAS). 
Nicotinamide is necessary for delta-6 desaturase and 
enhances the formation of various PUFAs and their 
products [8], suggesting that the neuroprotective action of 
nicotinamide against ethanol-induced FAS, as described by 
Alessandro Ieraci and Daniel Herrera [9], could be attributed 
to its action on these lipid pathways.  PLoS Medicine  |  www.plosmedicine.org 0700
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Authors’ Reply
We are grateful to Undurti Das for his suggestions regarding 
the possible mechanisms of action of nicotinamide in 
response to our research article [1,2]. He points to the 
metabolism of essential fatty acids and the inﬂ  ammatory 
responses observed after ethanol exposure. We, in fact, 
consider these important steps in the protection afforded 
by nicotinamide against ethanol-induced apoptosis, but, 
additionally, other possible mechanisms may be involved. 
The effects of nicotinamide appear to be very intricate and 
in need of more studies. For example, the effects of ethanol 
on delta-6 desaturase in the brain have not been studied in 
detail. The delta-6-desaturase increase was correlated with, 
and augmented, vitamin E levels in the brain [3]; however, in 
our preliminary studies, vitamin E did not ameliorate ethanol-
induced apoptosis. All of the mechanisms described below do 
not exclude the importance of those described by Das.
It has been shown that Bax mediates ethanol-induced 
apoptotic neuronal death in the developing brain [4]. 
Following an apoptotic stimulus, Bax translocates from 
the cytoplasm to the mitochondrial membrane, where it 
increases membrane permeability and promotes the release 
of cytochrome-c. This increase, in turn, induces activation 
of caspase-3, leading to cell death. Several mechanisms 
have been described to promote the translocation of Bax. 
Activation of the c-Jun N-terminal protein kinase (JNK) 
plays a critical role in Bax translocation [5]. Acute ethanol 
administration increases the activation of JNK in the 
postnatal cerebral cortex and striatum [6]. It has been shown 
that nicotinamide prevents the activation of JNK and the 
N-methyl-N-nitrosourea-induced apoptotic cell death in rat 
photoreceptor cells [7]. 
Inhibition of the phosphatidylinositol-3-kinase (PI3-K)/
Akt pathway is another cell death mechanism associated 
with the translocation of Bax [8]. Administration of ethanol 
decreases the activation of Akt in the developing postnatal 
rat brain [6]. Nicotinamide is able to increase the activation 
of Akt in primary hippocampal neuronal cell cultures, and 
this is necessary to protect against oxygen-glucose-deprivation 
(OGD)-induced apoptosis [9]. 
Several studies have pointed out that ethanol exposure 
increases the generation of reactive oxygen species in the 
developing brain [10]. Nicotinamide has been shown to 
act directly at the mitochondrial level by preventing the 
enhancement in mitochondrial permeability transition 
(MPT) pore opening and the release of cytochrome-c 
following exposure to OGD [9].
Cellular energy metabolism is another signiﬁ  cant factor 
that controls MPT pore formation, as the maintenance of 
mitochondrial membrane potential is an ATP-facilitated 
process. During oxidative stress, depletion of NAD, necessary 
for the production of ATP, is a critical step in precipitating 
cell death due to compromised energy supply. Nicotinamide 
administration increases the amount of NAD in the brain, 
and prevents its depletion and the consequent decrease of 
ATP [11]. 
We have demonstrated that nicotinamide prevents the 
ethanol-induced release of cytochrome-c and the following 
caspase-3 activation in brain development [2]. 
In conclusion, nicotinamide can prevent neuronal cell 
death by acting at different and probably complementary 
molecular levels.  
Daniel Herrera (dah2007@med.cornell.edu)
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Unique Author Identiﬁ  cation Number 
in Scientiﬁ  c Databases: A Suggestion
Matthew E. Falagas
There is an increasing trend toward the use of electronic 
databases of scientiﬁ  c information, such as the PubMed 
database of the National Library of Medicine and the various 
databases of the Institute for Scientiﬁ  c Information (ISI). 
These databases are frequently used nowadays for various 
purposes, including the peer-review process of papers 
submitted for publication in scientiﬁ  c journals. Most of the 
scientiﬁ  c journals now use a Web-based peer-review system that 
offers editors, peer reviewers, and publishers the capability to 
check the previous papers published by authors submitting a 
manuscript for consideration for publication [1]. In addition, 
these databases are frequently searched in an attempt to select 
potential speakers for scientiﬁ  c conferences and to obtain 
data for possible collaborators for a multicenter study, as well 
as in the process of evaluating the research productivity of 
scientists—which is being used for various purposes. 
However, it is widely known that a considerable proportion 
of authors share the same last name and ﬁ  rst initial. This 
seems to be the case for people of most ethnic heritages. In 
addition, authors of scientiﬁ  c publications do not frequently 
use their middle initial, which contributes to the confusion 
regarding the assignment of publications to the appropriate 
author. Frequently, it takes considerable effort and time to 
assign publications to the appropriate authors, particularly 
if there are authors that share the same last name and ﬁ  rst 
initial (with or without the middle initial). This is usually 
based on the pattern of research interests, as well as the 
institutional afﬁ  liations of the various authors with the same 
name. In fact, this task is often impossible.
In order to decrease the problems arising from authors 
with identical names, I suggest the introduction of a unique 
author identiﬁ  cation number (UAIN) in modern electronic 
databases of scientiﬁ  c information. I further suggest that 
such an identiﬁ  cation number may be hidden in the 
electronic databases, i.e., it is not necessary for the UAIN 
to appear when reviewing the record of a publication. This 
function of the electronic databases could start operating 
after the providers of the databases are given a reasonable 
time to prepare. To avoid the resources needed to update 
the electronic databases with the appropriate assignment of 
publications to each author, I suggest that the UAIN not be 
used retrospectively. In this case, the record of publications 
for a speciﬁ  c author would be divided into two parts. The 
publications that are prospectively connected to a given 
author with a speciﬁ  c UAIN would have an indicator denoting 
this, while older publications (before the introduction of the 
UAIN) would not have such an indicator.  
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Mistrust among Minorities and the 
Trustworthiness of Medicine
Matthew K. Wynia, Vanessa Northington Gamble
David Wendler and colleagues [1] have provided important 
data to help understand disparities in access to medical 
research among minorities. It is unfortunate, however, that 
they draw an unwarranted conclusion from a set of extremely 
heterogeneous studies. Worse still, by suggesting that the 
substantial body of research demonstrating how common it 
is for African Americans to mistrust the health-care system 
[2–4] is wrong, the authors imply that we do not need to 
come to terms with why this mistrust exists and how it should 
be addressed by the medical profession. 
Wendler et al. note the extreme heterogeneity of the trials 
included in their study, but they ignore how much this affects 
the reliability of the meta-analytic techniques they employ. 
First, the vast majority of the “more than 70,000” patients 
studied was only involved in survey research—where large 
differences in response rates between races are not generally 
seen. Looking only at the clinical trials, the numbers are 
much smaller and the data become much more difﬁ  cult 
to summarize. Among the seven surgical intervention 
trials studied, two have statistically signiﬁ  cant differences 
between minority enrollment and white enrollment. In 
one, whites had about 2.7 times greater odds of enrollment 
than minorities, while in the other, minorities had about 
1.6 times greater odds of enrollment than whites. In the 
ten clinical trials studied, three had statistically different 
enrollment rates; they, too, had greatly diverging results. 
For the most part, though, the clinical trials that Wendler 
et al. examined enrolled so few minority patients (in half 
of the studies, fewer than 50 minority patients were even 
asked to enroll), and they are so vastly different in design 
and objectives that very little information can be reliably 
gleaned from pooling their results. In fact, one of the largest 
trials included—the Minority-Based Community Clinical 
Oncology Program (MBCCOP) cancer trial, which included 
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more than 400 African Americans—was speciﬁ  cally designed 
to appeal to minority patients, making any assumptions 
about its generalizability to all medical research extremely 
suspect. It is well known that meta-analysis is subject to this 
sort of problem; statistical tricks simply can’t account for 
fundamental differences in studies. 
Despite these scientiﬁ  c weaknesses, Wendler et al. are 
right to conclude that it is inappropriate to focus on 
changing African Americans’ attitudes of mistrust, but not 
because those attitudes don’t exist. Many minorities don’t 
feel welcome and respected within the health-care system. 
Those who do come in have already crossed a threshold of 
trust, at least with their individual doctor. Those who don’t 
come in, of course, will never have the opportunity to be 
asked to enroll in a clinical trial. Instead, the reason it would 
be inappropriate to focus on changing patient attitudes is 
because these attitudes of mistrust are based on a history of 
untrustworthy behavior by the health professions, which must 
be acknowledged and rectiﬁ  ed. In other words, the medical 
profession should not focus on making minorities be more 
trusting; we should focus on ensuring that we are becoming 
trustworthy.  
Matthew K. Wynia (matthew.wynia@ama-assn.org)
American Medical Association
Chicago, Illinois, United States of America
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Authors’ Reply
The letter by Matthew Wynia and Vanessa Northington 
Gamble is based on an unfortunate conﬂ  ation of behavior 
and attitudes [1]. Our paper evaluated the often repeated 
claim that individuals from minority groups are less willing 
to participate in health research compared with non-
Hispanic whites [2]. That is, we evaluated what individuals 
do, whether they give consent, when invited to participate 
in health research. We did not and did not claim to evaluate 
individuals’ attitudes toward these requests or toward those 
who make them.
Our ﬁ  ndings, based on the existing empirical data, suggest 
that individuals from minority groups who are eligible and 
who are invited to participate agree to enroll in health 
research at rates similar to those of non-Hispanic whites. Wynia 
and Northington Gamble read this conclusion as a claim 
about individuals’ attitudes, as a denial of the “substantial 
body of research that demonstrates how common mistrust 
of the health-care system is among African Americans.” 
This conﬂ  ation of individuals’ behavior related to research 
enrollment with their levels of trust in the health-care system 
is surprising given that our focus on individuals’ willingness to 
participate in research is described in the title, and described 
throughout the text. Indeed, in an attempt to avoid just this 
conﬂ  ation, we explicitly wrote in the text that “we did not assess 
minority groups’ attitudes toward health research.”
Wynia and Northington Gamble also accuse us of ignoring 
the heterogeneity in the empirical data we found, and claim 
that “very little information can be reliably gleaned from 
pooling” these data. With this latter statement, we agree. 
As explained in the manuscript, the heterogeneity of the 
data suggests there is no simple relationship between one’s 
race or ethnicity and one’s willingness to participate in 
health research. While little else can be gleaned from these 
data, their very heterogeneity undermines the claim that 
individuals from minority groups are consistently less willing 
than non-Hispanic whites to participate in health research.  
David Wendler (DWendler@cc.nih.gov)
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Increasing the Participation: Another 
Factor
Ahmad A. Sabri, Mohammad Ahad Qayyum
The Perspective by Aziz Sheikh [1] has validly highlighted 
the lack of involvement of ethnic minorities in research 
studies, focusing on identifying the factors responsible for 
it. Apart from possible factors already discussed, another 
important factor that needs to be taken into consideration is 
the number of illegal immigrants in the United States and the 
United Kingdom. There are approximately 7 million illegal 
immigrants in the US (about 10% of 69.96 million ethnic 
minorities), and the number is growing by half a million each 
year [2,3]. The UK also shares the same trend, with 500,000 
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illegal immigrants (about 10.86% of 4.6 million ethnic 
minorities) [4,5]. 
In this regard, the apprehension of being traced as illegal 
immigrants poses a deﬁ  nite barrier to participating in any 
research activity. It is indeed a sensitive issue. Similar to the 
doctor–patient relationship, a conﬁ  dential channel should 
be ensured between the researcher and the participant. 
It is the duty of the researcher to explain during the 
time of consent that this research has nothing to do with 
participants’ citizenship status, and no information will be 
used in any way against them. Legislation must be passed 
to provide legal immunity to all participants regardless of 
their legal status. I believe adopting such methodology will 
increase the number of participants belonging to ethnic 
minorities. Moreover, research would be carried out on a 
truly representative structure of the local population.  
Ahmad A. Sabri (ayaz153@hotmail.com)
Mohammad Ahad Qayyum
Punjab Medical College
Faisalabad, Pakistan
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